Literature DB >> 27175249

Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors.

A M Carella1, G Beltrami1, G Catania1, G Pica1, C Ghiggi1, A Garuti1, A Carella1.   

Abstract

Autophagy inhibition has been shown to sensitize tumor cells to cell death induced by tyrosine kinase inhibitors (TKIs). The remarkable responses obtained in seven patients with the combination of clarithromycin and TKIs support the hypothesis that the inhibition of autophagy may make chronic myeloid leukemia cells sensitive to killing by TKIs.

Entities:  

Keywords:  autophagy; chronic myeloid leukemia; clarithromycin; tyrosine kinase inhibitors

Year:  2012        PMID： 27175249      PMCID： PMC4851206          DOI： 10.1038/leusup.2012.25

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN： 2044-5210


  8 in total

1.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.

Authors:  Francesca Gay; S Vincent Rajkumar; Morton Coleman; Shaji Kumar; Tomer Mark; Angela Dispenzieri; Roger Pearse; Morie A Gertz; John Leonard; Martha Q Lacy; Selina Chen-Kiang; Vivek Roy; David S Jayabalan; John A Lust; Thomas E Witzig; Rafael Fonseca; Robert A Kyle; Philip R Greipp; A Keith Stewart; Ruben Niesvizky
Journal:  Am J Hematol       Date:  2010-09       Impact factor: 10.047

2.  Clarithromycin attenuates autophagy in myeloma cells.

Authors:  Miki Nakamura; Yoshitaka Kikukawa; Motohiro Takeya; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2010-10       Impact factor: 5.650

Review 3.  Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.

Authors:  G Vignir Helgason; Maria Karvela; Tessa L Holyoake
Journal:  Blood       Date:  2011-06-21       Impact factor: 22.113

4.  Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia.

Authors:  A M Carella; E Lerma; M T Corsetti; A Dejana; P Basta; F Vassallo; M Abate; M Soracco; F Benvenuto; O Figari; M Podestá; G Piaggio; R Ferrara; M Sessarego; C Parodi; M Pizzuti; A Rubagotti; D Occhini; F Frassoni
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

Review 5.  mTOR regulation of autophagy.

Authors:  Chang Hwa Jung; Seung-Hyun Ro; Jing Cao; Neil Michael Otto; Do-Hyung Kim
Journal:  FEBS Lett       Date:  2010-01-18       Impact factor: 4.124

6.  Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.

Authors:  T C M Morris; P J Kettle; M Drake; F C G Jones; D R Hull; K Boyd; A Morrison; P Clarke; P O'Reilly; J Quinn
Journal:  Br J Haematol       Date:  2008-08-28       Impact factor: 6.998

Review 7.  Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.

Authors:  Bruno Calabretta; Paolo Salomoni
Journal:  Leuk Lymphoma       Date:  2011-01-21

8.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

Authors:  Cristian Bellodi; Maria Rosa Lidonnici; Ashley Hamilton; G Vignir Helgason; Angela Rachele Soliera; Mattia Ronchetti; Sara Galavotti; Kenneth W Young; Tommaso Selmi; Rinat Yacobi; Richard A Van Etten; Nick Donato; Ann Hunter; David Dinsdale; Elena Tirrò; Paolo Vigneri; Pierluigi Nicotera; Martin J Dyer; Tessa Holyoake; Paolo Salomoni; Bruno Calabretta
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808
  8 in total
  1 in total

Review 1.  Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.

Authors:  Fabien Muselli; Jean-François Peyron; Didier Mary
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.